.

.

American Society of Clinical Oncologists (ASCO) in Chicago yesterday report on exercise reducing psychological distress. Whether cancer outcome will be impacted is not yet known and will require study but inflammation may impact cancer progression.

.

.

Exercise is even more critical in those undergoing hormone therapies.

.

This was a small randomized study for seven weeks.

..

Patients receiving usual care experienced a 0.08 log10 increase in pro-inflammatory interleukin-6 production, while patients treated with an exercise program experienced a 0.03 log10 decrease in IL-6 (P<0.05), said Charles Kamen, PhD, research assistant professor at the University of Rochester Medical Center in New York.

.

In his oral presentation … Kamen and colleagues observed a similar relationship with another pro-inflammatory cytokine, interleukin-8. In the control patients, the researchers noted a 0.03 log10 increase compared with a 0.04 log10 decrease among the exercise group, Kamen said.

.

Using the Profile of Mood States (POMS), the research team determined that psychological distress decreased 5.17 points among the exercise group but increased 2.43 points in the patients who were in the usual control group (P=0.02).

.

“This study supports the use of exercise for cancer patients for reducing psychological distress and suggests a potential biological mechanism by which this improvement occurs, namely by reducing systemic inflammation,” Kamen said in his presentation….

.

The POMS scores were overall significantly in favor of the exercise group, and the subscales all trended in favor of exercise, except for the anger subscale in which there was virtually no change, Kamen said.

.

.

A review of the clinical use of low dose naltrexone appeared today by Younger, et al. from Stanford (see e-Pub below).

.

Naltrexone is one of the most important medications I have prescribed, alone or in combination with other medications for intractable chronic pain and/or treatment resistant Major Depressive Disorder or Bipolar Disorder. It has been most extensively used anecdotally and off label since 1985 for treatment of Multiple Sclerosis.

.

Naltrexone acts on two receptors in the central nervous system: (1) the opioid receptor and (2) the TLR4 receptor on glia.

..

(1) The opioid receptor is blocked by naltrexone. Naltrexone cannot be given to someone who uses opioid analgesics because it would cause a severe or unpleasant opioid withdrawal reaction. But in low dose, it can do better than opioids for relief of intractable pain. I would like to see it tried for pain, alone or in combination, before any opioid is started. And if on opioids, taper slowly off opioid in order to see how superior low dose naltrexone is. See case reports elsewhere on this site.

.

Low dose naltrexone is quite different than its use in high dose where it is FDA approved for addiction to alcohol and opiates. Naltrexone reduces craving. However, in high dose, it blocks the endorphins, the opiates that your brain produces, thus causing pain and depression.

.

(2) The TLR4 receptor was discovered by Bruce Beutler, MD, working at Scripps Research Institute. He won the Nobel Prize in 2011 for that profound work. The TLR4 receptor is found on the microglial cell in the central nervous system. The microglia far outnumber nerve cells in the brain and spinal cord. I discussed a small portion of the vast science of the importance of glia, your innate immune system and inflammatory cytokines, here. This research on glia, the innate immune system, is new, largely in the last 10 to 15 years.

.

One of the mechanisms by which opioids create pain is that opioids trigger glia to release pro-inflammatory cytokines, i.e. opioids create a neuroinflammatory response in a manner similar to endotoxin from bacteria. Opioids upset the balance of pro- and anti-inflammatory cytokines to create more pain. Naltrexone does the opposite by its action on the glial TLR4 receptor reducing pro-inflammatory cytokines and relieving pain.

.

Inflammation kills! Glia and/or the inflammation produced by glia are involved in many pathological processes: Alzheimer’s, Parkinsons, ALS, MS, chronic pain, depression, autoimmune disease, cancer, atherosclerosis. The TLR4 receptor is necessary for death or destruction of oligodendrocytes and myelin, as occurs in multiple sclerosis. Does that mean low dose naltrexone may play a role in modulating these conditions?

.

See reviews by distinguished Professor Linda Watkins, PhD, and Mark Hutchinson, PhD, on glia, neuroinflammation and the neuroimmunopharmacology of opioids. Besides glia, Watkins and Hutchinson have recently discovered Toll-like expression of neuronal receptors in pain states.

.

For access to articles on glia, cytokines and the TLR4 receptor, see the RSD Syndrome Association library of key publications. And donate to them. They have supported key research in pain when NIH gave less than half of 1% to pain research in 2006, now far less since the deadly the recession of 2008 and the ever threatened fight over funding the national debt.

.

Being interested in glia, and treating so many patients with Major Depressive Disorder who had failed other treatments, I did a review of depression and glia and found the same increase in pro-inflammatory cytokines in depression that are found in chronic pain. Since low dose naltrexone is anti-inflammatory, i.e. it modulates or resets the balance of pro-inflammatory and anti-inflammatory cytokines that are produced by glia, I felt it important to try in Major Depressive Disorder. Besides, I had seen its profound effect on so many different forms of intractable pain for many years. Use of LDN has never been associated with toxicity and rarely any side effects.

.

My patient had severe suicidal ideation with Major Depressive Disorder for more than three months, unchanged after treatment at a psychiatric center where she had stayed almost four weeks. She began with 4.5 mg in the office and 25 minutes later, on the drive home, her appetite returned! She walked in the house and her dad was astonished – she no longer walked like she was 105 years old! She had the energy to do her laundry and cook for the family for the first time in more than three months.

.

Another person for whom I prescribe naltrexone for Major Depression, wrote to me saying Massachusetts General, a Harvard Hospital, was starting clinical trials of low dose naltrexone for Major Depressive Disorder. Other new clinical trials of low dose naltrexone can be found here.

.

Jared Younger, PhD, from Stanford first published on the use of naltrexone in fibromyalgia – see my discussion here.

Authors Younger J, Parkitny L, McLain D.

Journal

Clin Rheumatol. 2014 Feb 15. [Epub ahead of print]

Affiliation

Abstract

Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that LDN may operate as a novel anti-inflammatory agent in the central nervous system, via action on microglial cells. These effects may be unique to low dosages of naltrexone and appear to be entirely independent from naltrexone’s better-known activity on opioid receptors. As a daily oral therapy, LDN is inexpensive and well-tolerated. Despite initial promise of efficacy, the use of LDN for chronic disorders is still highly experimental. Published trials have low sample sizes, and few replications have been performed. We cover the typical usage of LDN in clinical trials, caveats to using the medication, and recommendations for future research and clinical work. LDN may represent one of the first glial cell modulators to be used for the management of chronic pain disorders.

.

.

.

The material on this site is for informational purposes only.

It is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.

Improved spinal cord injury & inflammation in mice

.

.

Medical news November 17, 2009, announced that “UC Irvine pharmacology researchers have discovered a way to boost levels of a natural body fat that helps decrease inflammation, pointing to possible new treatments for allergies, illnesses and injuries related to the immune system.”

.

“For decades, it has been known that this fat, called palmitoylethanolamide (PEA), is a potent anti-inflammatory substance that reduces both allergic symptoms and occurrences of rheumatic fever, but researchers understood little about how PEA works.”

.

I”n a study appearing online in the Proceedings of the National Academy of Sciences, Daniele Piomelli, the Louise Turner Arnold Chair in Neurosciences at UCI, and colleagues found that levels of PEA are tightly regulated by immune system cells. In turn, PEA helps control the activity of these cells, which are called into action to fight infection, disease and injury in the body.”

.

They found a protein, an enzyme that breaks down molecules that control cell inflammation and deactivates PEA. They then created a novel compound that prevents the breakdown.

.

“When given to rodents, the compound increased the levels of PEA in their immune cells and reduced the amount of inflammation elicited by an inflammatory substance. Furthermore, when administered to the spinal cords of mice after spinal cord injury, the compound decreased inflammation associated with the trauma and improved the recovery of motor function.”

.

UCI is collaborating with the Italian Institute of Technology in Genoa to develop a range of immune-response drugs.

.

Palmitoylethanolamide is sold asPeaPure, a food supplement, available from the Netherlands and imported by a local pharmacyhere. I have submitted a paper for publication on the treatment of vulvodynia and proctodynia with PeaPure and a topical cream. That source will be posted once it is accepted.

.

I have been seeing some exciting responses to treatment of intractable pain with PeaPure. I invite others who use it to add comments below so that we may all learn from your experience.

.

.

.

~~~~~

The material on this site is for informational purposes only.

It is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.

.

.

Professor Bazbek Davletov now at Sheffield University, UK, reports his research that is featured on the cover of the October 2013 journal Bioconjugate Chemistry. He hopes the drug will cost around £1,000 a year, making it cheap enough for use on the NHS. It is authored by a 22-person team from 11 research institutes, including Lincoln University UK based Dr Enrico Ferrari.

.

Dr Ferrari joined the School of Life Sciences in October last year from the Medical Research Council’s Laboratory of Molecular Biology in Cambridge, where he took part in the development of a new way of joining and rebuilding molecules in the research group of Professor Bazbek Davletov who was then at the MRC.

Lincoln University, UK, heralds this promising discovery:

.

“Scientists have manufactured a new bio-therapeutic molecule that could be used to treat neurological disorders such as chronic pain and epilepsy.”

.

The molecule was able to alleviate hypersensitivity to inflammatory pain.

.

“Dr Ferrari, who is one of the lead authors of the study, said: “The toxins were split into parts so they were unable to function. Then later they were reassembled using a ‘zipping’ system so they can operate in a safe way. The re-engineered chimera toxin has very similar characteristics to Botox and is still able to block neurotransmission release, but the paralytic effect is a lot less. We then added a tetanus molecule which targets the chimera to where the pain signals travel towards the central nervous system.””

.

“Dr Ferrari added: “Many painkillers relieve the pain temporarily and have various side effects. The selling point of this molecule is that the pain relief could last up to seven months….””

.

~~~~~

The material on this site is for informational purposes only.

It is not a substitute for medical advice, diagnosis or treatment provided by a qualified health care provider.